Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Recession Stressful For Many Kids, Toughest On Poor And Uninsured
As the economy continues to falter, a poll released today shows that parents must make harder choices about how to spend what money they have, and children -- especially those who are uninsured or who are among the lowest income bracket -- are more at risk because of it.

Proteolix Presents Positive Clinical Data For Carfilzomib In Multiple Myeloma At The 2009 ASCO Annual Meeting
Proteolix, Inc. presented results from the company"s most advanced clinical trial of single-agent carfilzomib demonstrating anti-cancer activity and progression-free survival in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.
News of the day
FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
Boston Scientific Corporation (NYSE: BSX) announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Medical Devices

Is P90RSK A New Therapeutic Target For Liver Fibrosis?

Cirrhosis is a world wide, bad prognosis liver disease and characterized by excessive collagen deposition and liver function damage. In our previous work, p90RSK is observed significantly up-regulated in association with elevated collagen type I levels in rat liver fibrosis. But detail mechanism of this phenomenon is still unknown. Now, there is a research article published on May 7, 2009 in the World Journal of Gastroenterology that addresses this problem. The research team led by Professor Zhu from Department of Gastroenterology, Jinling Hospital observed the mechanism between p90RSK and collagen type I in vivo and in vitro. In fibrotic liver tissue, p90RSK was over-expressed and located in activated HSC, which had a significant positive correlation with collagen type I levels. In HSC-T6 cells transfected with RNAi targeted to p90RSK, the expression of collagen type I was down regulated according with that of p90RSK. However, collagen type I promoter activity was not alternated with up-regulation or down-regulation of p90RSK expression. Otherwise, p90RSK RNAi inhibited the proliferation of HSC significantly. These results indicate that P90RSK was a critical element in activation of HSC, which is primarily responsible for excessive collagen expression via the initiation of HSC proliferation during liver fibrosis. Lacking of the knowledge about pathological proceeding of liver fibrosis results in the lack of effective method to prevent and treat liver fibrosis. These results prefer a new view of p90RSK on liver fibrosis, and thus may provide a new therapeutic target to liver fibrosis. Reference: Yang MF, Xie J, Gu XY, Zhang XH, Davey AK, Zhang SJ, Wang JP, Zhu RM. Involvement of 90-kuD ribosomal S6 kinase in collagen type ò…  expression in rat hepatic fibrosis. World J Gastroenterol 2009; 15(17): 2109-2115 http://www.wjgnet.com/1007-9327/15/2109.asp Correspondence to: Ren-Min Zhu, Professor, Department of Gastroenterology, Jinling Hospital, Second Military Medical University, Zhongshan East Road 305, Nanjing 210002, Jiangsu Province, China. Lin Tian World Journal of Gastroenterology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009